SCHEMBL17879527

SCHEMBL17879527

COC(=O)CC(N)c1ccc([N+](=O)[O-])cc1C

nearest known ligand 0.48

Predicted protein targets (top 17)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 8/20 0.46
TDP1 Q9NUW8 2/20 0.46
CYP3A4 P08684 2/20 0.46
MAPT P10636 1/20 0.45
TSHR P16473 2/20 0.45
SMN1; SMN2 Q16637 1/20 0.43
LMNA P02545 1/20 0.43
TNF P01375 1/20 0.43
GLA P06280 1/20 0.43
KMT2A Q03164 2/20 0.42
MEN1 O00255 1/20 0.42
HTT P42858 1/20 0.42
POLB P06746 1/20 0.42
L3MBTL1 Q9Y468 1/20 0.41
ADRB2 P07550 1/20 0.41
ADRB1 P08588 1/20 0.41
ADRB3 P13945 1/20 0.41

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
Hydrochloric Acid SCHEMBL16970698 0.99 ALDH1A1 (0.45) ALDH1A1TDP1CYP3A4MAPTTSHR
SCHEMBL17879526 0.89 LMNA (0.46) ALDH1A1TDP1CYP3A4MAPTTSHR
SCHEMBL18120663 0.86 ALDH1A1 (0.46) ALDH1A1TDP1CYP3A4MAPTTSHR
SCHEMBL16970721 0.85 ALDH1A1 (0.50) ALDH1A1TDP1CYP3A4MAPTTSHR
SCHEMBL10902 0.84 ALDH1A1 (0.46) ALDH1A1MAPTSMN1; SMN2LMNATNF
Hydrochloric Acid SCHEMBL28112642 0.83 ALDH1A1 (0.49) ALDH1A1TDP1CYP3A4MAPTTSHR
SCHEMBL16979680 0.82 MAPT (0.45) ALDH1A1TDP1CYP3A4MAPTTSHR
SCHEMBL14008890 0.80 ALDH1A1 (0.46) ALDH1A1CYP3A4MAPTSMN1; SMN2LMNA
SCHEMBL4833185 0.80 NPC1 (0.48) ALDH1A1MAPTLMNATNFKMT2A
SCHEMBL16970776 0.79 MAPT (0.47) ALDH1A1TDP1MAPTSMN1; SMN2LMNA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-10034847-B2 Beta-substituted beta-amino acids and analogs as chemotherapeutic agents QUADRIGA BIOSCIENCES, INC. (US) 2018-07-31 US disclosed
WO-2017024009-A1 BETA-SUBSTITUTED BETA-AMINO ACIDS AND ANALOGS AS CHEMOTHERAPEUTIC AGENTS AND USES THEREOF QUADRIGA BIOSCIENCES, INC. (US) 2017-02-09 WO disclosed
US-20160185710-A1 BETA-SUBSTITUTED BETA-AMINO ACIDS AND ANALOGS AS CHEMOTHERAPEUTIC AGENTS QUADRIGA BIOSCIENCES, INC. 2016-06-30 US disclosed
US-20160185710-A1 BETA-SUBSTITUTED BETA-AMINO ACIDS AND ANALOGS AS CHEMOTHERAPEUTIC AGENTS QUADRIGA BIOSCIENCES, INC. 2016-06-30 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-10034847-B2 Beta-substituted beta-amino acids and analogs as chemotherapeutic agents SLC7A1, SLC3A2, SLC1A5 ALDH1A1 440/4885TDP1 3140/4885CYP3A4 1711/4885
US-20160185710-A1 BETA-SUBSTITUTED BETA-AMINO ACIDS AND ANALOGS AS CHEMOTHERAPEUTIC AGENTS SLC7A1, SLC3A2, SLC1A5 ALDH1A1 440/4885TDP1 3140/4885CYP3A4 1711/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.